Fractyl Health (GUTS) Retained Earnings (2023 - 2026)
Fractyl Health's (GUTS) quarterly Retained Earnings came in at $568.4 million in Q1 2026, up 229.48% YoY from $172.5 million in Q1 2025, and up 202.19% on a QoQ basis from -$556.3 million in Q4 2025.
Fractyl Health (GUTS) Retained Earnings (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Retained Earnings data on file, last reported at $568.4 million in Q1 2026.
- Quarterly Retained Earnings rose 229.48% year-over-year to $568.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $568.4 million (up 229.48% YoY) and the FY2025 annual result came in at -$556.3 million, down 225.36% from the prior year.
- Retained Earnings improved to $568.4 million in Q1 2026, from -$556.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $568.4 million in Q1 2026 to a low of -$556.3 million in Q4 2025.
- A 4-year average of $102.5 million and a median of $436.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings tumbled 225.36% — and 2026, when it soared 229.48%.
- Tracing GUTS's Retained Earnings over 4 years: stood at -$346.6 million in 2023, then surged by 228.02% to $443.7 million in 2024, then plunged by 225.36% to -$556.3 million in 2025, then soared by 202.19% to $568.4 million in 2026.
- The last three Retained Earnings figures came in at $568.4 million (Q1 2026), -$556.3 million (Q4 2025), and $509.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | -572.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -572.60 Mn |
| Mar 31, 2026 | 568.42 Mn |
| Dec 31, 2025 | -556.26 Mn |
| Sep 30, 2025 | 509.36 Mn |
| Jun 30, 2025 | -466.90 Mn |
| Mar 31, 2025 | -439.00 Mn |
| Dec 31, 2024 | 443.73 Mn |
| Sep 30, 2024 | 440.66 Mn |
| Jun 30, 2024 | 437.92 Mn |
| Mar 31, 2024 | 434.12 Mn |
| Dec 31, 2023 | -346.62 Mn |